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Recent data, including a number of controversial 
findings from clinical COVID-19 studies, have initiated an 
intense debate regarding central nervous system (CNS) 
involvement in SARS-CoV-2 infection-associated pathol-
ogies and overall outcomes. In our opinion, involvement 
of the brain may be an important contributor to the 
highly complex pathophysiology caused by SARS-CoV-2 
and lessons from studies on stroke and systemic in-
flammation provide important clues. 
Numerous CNS symptoms, including loss of smell 
and taste, headache, dizziness, nausea, seizures and 
respiratory distress have been reported in COVID-19. 
Several neurological syndromes, such as stroke, enceph-
alitis, epilepsy, and Guillain-Barre syndrome have been 
associated with COVID-19. More recently, large-vessel 
occlusive stroke has been described in younger patients 
without typical COVID-19 symptoms1-3. In addition, his-
tory of stroke is associated with increased severity of 
COVID-194. These observations highlight the brain as an 
important target of this multiorgan disease. While neu-
roinvasion of SARS-CoV-2 has been associated with cer-
ebral thrombosis, hemorrhagic infarction, demyelinating 
lesions and encephalopathy (termed as Neuro-COVID)5,6, 
it has also been suggested that some respiratory symp-
toms in patients with COVID-19 could indicate neurolog-
ical involvement7. Post-mortem examination of a series 
of patients with positive polymerase chain reaction test-
ing for COVID-19 in pleural effusions revealed negative 
testing in all cerebrospinal fluid (CSF) samples along with 
no signs of encephalitis or CNS vasculitis8. This data may 
suggest that brain involvement in COVID-19 does not 
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play a major role in the disease pathogenesis. However, 
it appears difficult to draw firm conclusions from these 
observations. SARS-CoV-2 might not be detectable in the 
CSF due to low viral load, increased clearance, or the 
sensitivity of detection5, while macroscopic analysis may 
not be sufficient to reveal the presence of infection in 
the brain tissue. Nevertheless, other arguments also 
indicate that neurological symptoms reported to date 
may be nonspecific and not necessarily imply CNS dis-
ease, while respiratory failure alone does not suggest 
CNS invasion by SARS-CoV-29. However, in the absence 
of comprehensive neuropathological analysis, the extent 
and anatomical distribution of SARS-CoV-2 infection in 
the CNS remain unanswered. The robust inflammatory 
and prothrombotic response directly and indirectly af-
fecting the CNS could explain some of the major neuro-
logical complications, which may be complemented by 
effects of possible SARS-CoV-2 infection in the brain. 
Coronaviruses have long been recognised as po-
tentially neurovirulent microorganisms10. Neuroinva-
siveness of severe acute respiratory syndrome corona-
virus (SARS-CoV) and Middle East respiratory syndrome 
coronavirus (MERS-CoV), has been previously reported 
with pronounced infection in brainstem nuclei involved 
in respiratory and cardiovascular control2,11. Based on 
these data, SARS-CoV-2 might also reach the CNS via 
multiple routes. In viraemia, SARS-CoV-2 binds to the 
angiotensin-converting enzyme-2 (ACE2) receptor on the 
endothelium and, after crossing the blood-brain barrier 
(BBB), also binds to neurons expressing the receptor12. 
One of the currently available case reports with post-
mortem neuropathology limited to electron microscopic 
examination in a frontal lobe sample demonstrates the 
virus in endothelial cells with features suggestive of 
transit of the virus towards the neuropil, and neuronal 
‘viral-like’ particles in cytoplasmic vacuoles13. Via the 
olfactory route, the virus infects the olfactory epitheli-
um, enters the nervous system across the cribriform 
plate through axons of olfactory bulb neurons, and then 
infects the sustentacular cells that maintain the integrity 
of olfactory sensory neurons. SARS-CoV-2 may also enter 
and spread via the cerebral lymphatic (glymphatic) 
drainage system since the virus can infect the endotheli-
al cells of the olfactory lymphatic system which connect 
to the brain12,14-16. In addition, similar to herpesviruses 
or the avian influenza virus, SARS-CoV-2 could reach the 
brain via peripheral nerves, possibly via retrograde 
transport and trans-synaptic spread17-19. Deficient sys-
temic immune response due to older age, chronic dis-
ease or immunosuppressive therapy, altered ACE2 ex-
pression in diabetic or hypertensive patients, cerebro-
vascular disease (major risk factors for COVID-19-
associated mortality)1,4, as well as vascular inflammation 
or impaired blood-brain barrier (BBB) function in aged or 
comorbid patients could also increase the risk and sever-
ity of infection. If CNS infection occurs, the outcome 
largely depends on the ability of the CNS immune sys-
tem to control the spread of the virus. Studies on neuro-
tropic virus infection suggest that microglia, the main 
inflammatory cells of the CNS, are important in control-
ling both the spread of the virus and shaping the cere-
bral inflammatory response. This key role of microglia 
has been experimentally demonstrated in coronavirus, 
herpesvirus, Theiler’s virus and vesicular stomatitis virus 
infection among others20-24. Importantly, lack of normal 
microglial function not only increases viral spread in the 
brain, but is also associated with markedly worsened 
neurological symptoms (motor function deficits, neu-
ronal injury, brain oedema, seizures, etc.) and increased 
mortality in animal models20-24. Microglial phenotype is 
heavily influenced by age, comorbidities and systemic 
inflammation25. Therefore, it is likely that compromised 
microglial function is an important contributor to poor 
outcome in Neuro-COVID, especially if brain areas in-
volved in respiratory, cardiovascular and neuroendo-
crine control are affected by SARS-CoV-2. Effective anti-
viral drug delivery through the BBB may therefore be 
important in the management of neurological complica-
tions. 
Irrespective of whether CNS SARS-CoV-2 infection 
occurs, the cerebral effects of systemic inflammation 
associated with “cytokine storm” and prothrombotic 
state have profound impact on outcome in severe 
COVID-19 cases. High serum levels of inflammatory cy-
tokines, such as IL-6, predict poor outcome26 and may 
contribute to cardiac- and respiratory arrest, coma and 
multiorgan failure through complex mechanisms that 
include microcirculatory deficits, hypotension, oedema 
and thrombosis. Circulating inflammatory cytokines 
stimulate the autonomic nervous system and the hypo-
thalamic-pituitary-adrenal (HPA) axis with major impact 
on blood pressure and flow, respiration and neuroendo-
crine function. The autonomic nervous system and HPA 
axis also play an important role in the regulation of im-
mune cell responses, cytokine production, cell trafficking 
and cell death via both humoral and neural mechanisms. 
The sustained increase in serum adrenaline, noradrena-
line and cortisol levels due to prolonged autonomic and 
HPA axis activation eventually lead to dysregulation of 
inflammatory responses. This, in line with excessive 
cytokine production, results in insufficient elimination of 
infectious agents. The lymphopenia due to apoptosis 
and impaired lymphopoiesis shifts immune cell balance 
towards excessive monocyte and granulocyte load, fur-
ther increasing the production myeloid cell-derived 
proinflammatory cytokines. 
The excessive systemic inflammatory response also 
contributes to the neurological complications via direct 
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and indirect actions. Findings from clinical and experi-
mental stroke studies with preceding or post-stroke 
infection may help to shed light on the mechanisms of 
COVID-19-related neurological impairment. Stroke in 
apparently healthy young- and middle-aged people with 
rapid formation of thrombi in the cerebral circulation 
and high mortality of older patients with chronic in-
flammatory disease collectively suggest a high impact of 
altered coagulation in patients with COVID-1927,28. Infec-
tions in general (e.g. seasonal flu) increase stroke inci-
dence29. As known from studies of viral and bacterial 
sepsis and from comorbid models of stroke, increased 
systemic inflammatory burden promotes vascular in-
flammation, platelet activation and alters coagulation 
cascades, leading to a procoagulant state leading to 
thrombosis and disseminated intravascular coagulation. 
Such coagulopathy, predictive of worse clinical outcome, 
has been reported in COVID-1930,31. This promotes 
thrombus formation in both veins and arteries – a 
known feature of severe COVID-19 with thromboembol-
ic complications reported in around one third of infected 
patients32. The cerebrovascular endothelial cells have 
particularly high sensitivity to proinflammatory cytokines 
and SARS-CoV-2 infection could further boost the ex-
pression of adhesion molecules and increase vascular 
permeability. Brain injury and mortality are generally far 
more severe in patients with additional stroke risk fac-
tors (e.g. in obese, diabetic, hypertensive patients or 
after infection), similarly to that seen in experimental 
stroke models. As an example, localized infection of the 
lungs by influenza virus or Streptococcus pneumoniae 
leads to marked increases in circulating proinflammatory 
cytokines, endothelial activation (indicated by increased 
levels of adhesion molecules) and platelet aggregation. 
These infection-driven changes are associated with 
augmented brain inflammation and leukocyte recruit-
ment, leading to increased neuronal injury and worse 
neurological outcome33-35. Targeted blockade of proin-
flammatory cytokines (e.g. IL-6, IL-1 or TNF) or platelet-
endothelial interactions attenuated infection-induced 
brain injury in experimental models33,34,36-38, while the 
potential efficacy of IL-6 receptor antagonist Tocilizumab 
to reduce mortality in severe COVID-19 cases has been 
suggested39. 
Recent reports have described patients with is-
chaemic stroke complicating COVID-19 infection, often 
manifesting as large-vessel infarcts occurring in multiple 
territories and associated with features of prothrombot-
ic coagulopathy3,40,41. However, these small case series 
may not be representative of wider clinical practice, and 
no causal relationship has yet been established between 
COVID-19 infection and stroke. Other mechanisms may 
also be relevant, such as destabilisation of atheromatous 
plaques resulting in thrombosis and cerebral atheroem-
bolism, atrial fibrillation in critically ill patients causing 
thromboembolism of cardiac origin, or haemorrhage 
secondary to microangiopathy and cerebral vasculitis. 
Importantly, patients may also acquire SARS-CoV-2 in-
fection following stroke. Suppression of both innate and 
adaptive immune response is well-documented after 
stroke, driven by autonomic nervous system failure and 
activation of the HPA axis, which could exacerbate sub-
clinical infection, or increase susceptibility to nosocomial 
infection. 
An important issue to address is whether neurolog-
ical manifestations (reported in up to one third of cases 
with different severity of infection1,42) result from sys-
temic effects on the brain, direct CNS infection by SARS-
CoV-2, or both, and if the latter is a major contributor to 
COVID-19-related severe illness and mortality. Firm 
conclusions cannot be drawn at this stage due to limited 
data availability, but it is likely that the impact of CNS-
related effects on disease outcome is considerable. Most 
neurological manifestations appear to occur early in the 
illness, preceding severe respiratory distress and the 
need for mechanical ventilation, while several patients 
are admitted to the hospital merely based on neurologic 
manifestation with no respiratory symptoms1. At this 
time, data are largely from single case reports. For ex-
ample, occurrence of neurological symptoms such as 
fever, anosmia, dysgeusia, headache and possible sei-
zure in line with respiratory distress and severe ventila-
tor asynchronies were found in a patient where autopsy 
later confirmed the presence of SARS-CoV-2 infection in 
the brain. Findings included widespread tissue damage 
involving the neurons, glia, nerve axons, and myelin 
sheath, progressively more severe from the olfactory 
nerve to the gyrus rectus and to the brainstem43. A re-
cent report showed that after positive diagnosis for 
SARS-CoV-2, a patient developed complete anosmia and 
dysgeusia, with MRI showing signs of bilateral olfactory 
bulb oedema, followed by normalization of both sensory 
symptoms and MRI signal by day 1444. Another report 
found that 44% of patients admitted to the intensive 
care unit with COVID-19 and neurological symptoms 
showed CNS abnormalities on MRI, which included corti-
cal (frontal, parietal, occipital, temporal, insular) and 
deep white matter FLAIR signal abnormalities, in the 
absence of SARS-CoV-2 in the CSF (50% of cases tested). 
Thus, while focal neuropathologies appear to be fre-
quent in severe cases, the extent of associated brain 
infection remains unclear presently. Of note, the inci-
dence of epileptiform discharges, seizure-like events and 
new onset encephalopathy is more than two-fold higher 
in acutely ill COVID-19 patients with neurological symp-
toms compared to non-infected patients, but it is not 
known if this is through direct or indirect actions on the 
CNS45. While SARS-CoV-2 infection shares many similari-
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ties with bacterial sepsis, the inflammatory response 
was considered more modest (e.g. lower IL-6 levels), and 
progressive and profound suppression of adaptive im-
munity was noted in COVID-19 relative to sepsis46. 
Therefore, further studies are required to assess the 
nature of systemic inflammatory changes and their im-
pact on neurological symptoms and disease outcome. 
In conclusion, the available evidence strongly indi-
cates that the brain is an important target of SARS-CoV-2 
and the impact of its brain-related pathophysiology on 
survival and outcome in COVID-19 is substantial. While 
diagnostic efforts and research studies to investigate the 
presence of infection in the brain and to reveal the 
mechanisms of both central and systemic inflammation 
in COVID-19 are necessary, lessons from previous work 
on infection, stroke and systemic inflammation should 
be considered. Regarding the clinical management of 
COVID-19 patients, immune modulatory therapies are 
attractive candidates. In this respect it will be intriguing 
to learn the outcomes of ongoing clinical trials of anti-
cytokine therapies, including anakinra (IL-1 receptor 
antagonist) and Tocilizumab (IL-6 receptor antibody). 
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